Top interaction networks for the 67 DEG in PBC of patients with abnormal decline of LVEF after DOX-chemotherapy identified by Ingenuity pathway analysis.

<p>(A) Network 1 “Connective tissue disorder, Immunological disease, Inflammatory disease”; (B) Network 2 “Cellular movement, Hematological system development and function, Immune cell trafficking”. Red filled (up-regulation) and Green filled (down-regulation); Blue line (leads to inhibition); Orange line (leads to activation); Black line (effect not predicted).</p

Ingenuity biological function analysis of DEG associated with 1 dose of DOX-based chemotherapy in patients with abnormal decline of LVEF at completion of chemotherapy.

<p>The most enriched “biological functions” of this dataset identified using Ingenuity software were “cell-to-cell signaling” (p-value = 1.40E-07–3.2E-02), “cellular movement” (p value = 2.23E-04–2.02E-02) and “cellular development” (p value = 2.85E-04–2.89E-03). The most represented “diseases and disorders” were “connective tissue disorders” (p value 2.53E-12–2.57E-02), “inflammatory diseases” (p value = 2.53E-12–3.13E-02), “skeletal and muscular disorders” (2.53E-12–1.23E-02) and “immunological diseases” (p value = 5.59E-12–3.12E-02).</p

Cardiac function of women with breast cancer, treated with DOX-based chemotherapy.

<p>MUGA scan was performed before the start of DOX chemotherapy and at its completion.</p

Age-associated differences in the gene expression.

<p>Age-associated differences in the gene expression.</p

Unique DOX-induced DEG in patients with abnormal decline of LVEF after one dose of DOX-based chemotherapy (p<0.05, FDR<0.1).

<p>Unique DOX-induced DEG in patients with abnormal decline of LVEF after one dose of DOX-based chemotherapy (p<0.05, FDR<0.1).</p

Volcano plots of log2 fold change (x-axis) versus –log10 of unadjusted P-values (y-axis), representing the probability that the gene is differentially expressed in PBC of breast cancer patients treated with DOX-based chemotherapy in data of average before versus after one dose of DOX-based chemotherapy.

<p>(A) comparison of average before vs after of all patients; (B) average before vs after in patients with normal LVEF after the completion of chemotherapy; (C) average before vs after in patients with abnormal LVEF after the completion of chemotherapy. P<0.05; FDR<0.1.</p

Discovery analysis: SNP association with ALS outcome using GENEVA controls only.

<p>Discovery analysis: SNP association with ALS outcome using GENEVA controls only.</p

Replication and pooled analysis: SNP association with ALS survival.

<p>Replication and pooled analysis: SNP association with ALS survival.</p

Discovery analysis: SNP association with ALS outcome using GENEVA+WTCCC2 controls.

<p>Discovery analysis: SNP association with ALS outcome using GENEVA+WTCCC2 controls.</p

Quantile-quantile plots.

<p>a) ALS outcome with GENEVA controls only; b) ALS outcome with GENEVA and WTCCC2 controls included.</p